A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer

NCT07318883 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

720

Enrollment

INDUSTRY

Sponsor class

Conditions

Squamous NSCLC

Interventions

DRUG: HLX07
DRUG: HLX07 placebo
DRUG: Serplulimab
DRUG: Pembrolizumab
DRUG: Carboplatin
DRUG: Paclitaxel or Nab-Paclitaxel

Sponsor

Shanghai Henlius Biotech